NASDAQ:NOVN - Novan Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.2791 -0.12 (-8.58 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$1.2791
Today's Range$1.25 - $1.4599
52-Week Range$1.23 - $4.61
Volume138,325 shs
Average Volume87,371 shs
Market Capitalization$36.48 million
P/E Ratio-0.55
Dividend YieldN/A
Beta1.01
Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NOVN
Previous Symbol
CUSIPN/A
Phone919-485-8080

Debt

Debt-to-Equity RatioN/A
Current Ratio1.64
Quick Ratio1.64

Price-To-Earnings

Trailing P/E Ratio-0.55
Forward P/E Ratio-1.17
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.14 million
Price / Sales15.58
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.09) per share
Price / Book-14.21

Profitability

EPS (Most Recent Fiscal Year)($2.32)
Net Income$-37,120,000.00
Net Margins-1,087.54%
Return on Equity-999.64%
Return on Assets-82.50%

Miscellaneous

Employees59
Outstanding Shares26,060,000
Market Cap$36.48 million
OptionableNot Optionable

Novan (NASDAQ:NOVN) Frequently Asked Questions

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) issued its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.24. The company earned $0.10 million during the quarter, compared to the consensus estimate of $10.80 million. Novan had a negative return on equity of 999.64% and a negative net margin of 1,087.54%. View Novan's Earnings History.

When is Novan's next earnings date?

Novan is scheduled to release their next quarterly earnings announcement on Tuesday, March 26th 2019. View Earnings Estimates for Novan.

What price target have analysts set for NOVN?

3 analysts have issued twelve-month price targets for Novan's stock. Their predictions range from $6.00 to $14.00. On average, they expect Novan's share price to reach $8.6667 in the next year. This suggests a possible upside of 577.6% from the stock's current price. View Analyst Price Targets for Novan.

What is the consensus analysts' recommendation for Novan?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novan.

What are Wall Street analysts saying about Novan stock?

Here are some recent quotes from research analysts about Novan stock:
  • 1. HC Wainwright analysts commented, "We eagerly anticipate, any day now, data from the Phase 2 dose-ranging study of SB206—topical nitric oxide (NO) gel—for molluscum contagiosum. We see molluscum as a large, underserved pediatric dermatology opportunity, with no FDA approved Rx treatments, and it is currently the key contributor to our Novan valuation. If Phase 2 is positive, with SB206 demonstrating meaningful molluscum lesion clearance rates at 12-weeks and good tolerability, it should be a transformational catalyst for Novan. Note that the only molluscum comparable, Verrica Pharmaceuticals (VRCA; not rated), which has positive open-label molluscum Phase 2 data and Phase 3 expected in 1Q19, has a $350M market cap—dramatically higher than Novan’s current $68M market cap." (11/6/2018)
  • 2. According to Zacks Investment Research, "Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company's product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through Nitricil technology(TM). Novan, Inc. is based in Durham, United States. " (10/10/2018)

Has Novan been receiving favorable news coverage?

News articles about NOVN stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novan earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future.

Who are some of Novan's key competitors?

Who are Novan's key executives?

Novan's management team includes the folowing people:
  • Mr. G. Kelly Martin, CEO & Director (Age 59)
  • Dr. Nathan Stasko, Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
  • Mr. Jeff N. Hunter, Exec. VP, Chief Bus. Officer & Company Sec. (Age 61)
  • Ms. Paula Brown Stafford, Chief Devel. Officer & Director (Age 53)
  • Mr. Andrew J. Novak, VP & Chief Accounting Officer

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Novan's major shareholders?

Novan's stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.34%). Company insiders that own Novan stock include G Kelly Martin, John W Palmour and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.

Which institutional investors are buying Novan stock?

NOVN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Novan stock in the last two years include G Kelly Martin, John W Palmour and Robert Alexander Ingram. View Insider Buying and Selling for Novan.

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $1.2791.

How big of a company is Novan?

Novan has a market capitalization of $36.48 million and generates $2.14 million in revenue each year. The company earns $-37,120,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Novan employs 59 workers across the globe.

What is Novan's official website?

The official website for Novan is http://www.novantherapeutics.com.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]


MarketBeat Community Rating for Novan (NASDAQ NOVN)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  321
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Featured Article: What is a conference call?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel